BDI, "Ellison Confirms Efficacy of Brain Cancer Drug 'DBD' in Solid and Hematologic Tumors"

[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 1st that its subsidiary Ellison's brain cancer treatment drug 'DBD' has confirmed efficacy in both solid tumors and hematologic cancers, and plans to proceed with Phase 3 clinical trials by mid-next year.

DBD is a new drug candidate developed by the NCI (National Cancer Institute), and Phase 1 and 2 clinical trials have been conducted in various locations so far. Based on the already secured safety database, Ellison modified the molecular structure of an existing anticancer drug and obtained new patents in the United States and Europe. Ellison holds exclusive global rights for all indications of DBD.

A VIDI official stated, "After recently receiving a progress report on DBD from Ellison, it was confirmed that DBD can replace existing therapeutic drugs, and in this case, an annual revenue of 150 billion KRW in the US market can be expected," adding, "This is because DBD is an alkylating agent drug equivalent to temozolomide (TMZ), known as the standard treatment for glioblastoma, and can replace TMZ."

Existing brain cancer treatment drugs have very low blood-brain barrier permeability, resulting in limited therapeutic effects. Unlike existing treatments, DBD is an oral cytotoxic anticancer agent that bypasses the blood-brain barrier and has confirmed efficacy in both solid tumors and hematologic cancers. The company explained that it is effective not only for newly diagnosed brain tumor patients but also for patients resistant to standard anticancer chemotherapy.

This content was produced with the assistance of AI translation services.